Isis Experimental Drug Lowers Cholesterol, but Has Damaging Side Effects
By Don Bauder
November 17, 2009
Stock of Carlsbad-based biotech Isis Pharmaceuticals plunged 17.01% today to $11.12 on good/bad news. Isis is developing a drug with Genzyme for reducing cholesterol in an extremely rare genetic disorder in which a gene that should remove cholesterol from the body is missing. A phase III study indicated that the drug, mipomersen, cut levels of "bad" LDL cholesterol by 25% in patients with the disorder. But it also caused elevated liver enzymes in 12% of patients -- a sign the drug may have damaging liver effects. Isis and Genzyme said that none of the patients showed signs of permanent liver damage.
Thanks for this info. I have a rare disorder that is kind of like this. Several years ago my triglicerides rose to 8000!!! And I weigh 180, and was in pretty good health. My body was not breaking down the carbs and cholestoral. I will keep an eye on this medical development.
Response to post #1: You have an affliction that is exceedingly rare. Best, Don Bauder
Post a comment
Commenting requires registration.
If you don't wish to register at this time, but still want to post a comment, please use our guest Username: sdblogger and Password: sdblogger.